Pharmaceutical Contract Manufacturing And Research Services Market Size, Share & Trends Analysis Report By Service (Manufacturing, Research), By Region- Global Industry Analysis, Share, Growth, Regional Outlook and Forecasts, 2023-2032

The global pharmaceutical contract manufacturing and research services market size was exhibited at USD 215.57 billion in 2022 and is projected to hit around USD 436.09 billion by 2032, growing at a CAGR of 7.3% during the forecast period 2023 to 2032.

Pharmaceutical Contract Manufacturing And Research Services Market Size, 2023 to 2032

Key Pointers:

  • By service, the manufacturing segment dominated the market in 2022. In this segment, Active Pharmaceutical Ingredient (API) / bulk drugs held the largest revenue share of over 62.0% in 2022. Pharmaceutical companies prefer outsourcing services for API research and manufacturing owing to the reduction in the cost of production of APIs
  • In the manufacturing service segment, finished dose formulations are expected to register the fastest CAGR of 7.8% from 2023 to 2032
  • The research service segment is further segmented based on therapeutic area, wherein oncology held a significant share of over 25.0% in 2021 and is anticipated to maintain its lead in the coming years owing to the high disease burden of cancer worldwide
  • CMOs/CDMOs with the ability to establish facilities in emerging countries are expected to drive the market. The contract service sector is in its infancy in countries, including Brazil, India, and China
  • Companies can position themselves for strong growth, given that demand is expected to expand rapidly in the coming years. Increased competitiveness in the contract service sector is anticipated to ultimately benefit the sector growth
  • China, Japan, and India are projected to witness tremendous growth in the forecast period owing to high disease prevalence

Pharmaceutical Contract Manufacturing And Research Services Market Report Scope

Report Coverage

Details

Market Size in 2023

USD 231.3 Billion

Market Size by 2032

USD 436.09 Billion

Growth Rate from 2023 to 2032

CAGR of 7.3%

Base year

2022

Forecast period

2023 to 2032

Segments covered

By Service

Regional scope

North America; Europe; Asia Pacific; Central and South America; the Middle East and Africa

Key companies profiled

Catalent; Pharmaceutical Product Development LLC; AbbVie; Baxter BioPharma Solutions; Patheon; Grifols International, S.A.; Dalton Pharma Services; Boehringer Ingelheim Biopharmaceuticals GmbH; Lonza AG

 

The rising investments in R&D, increasing demand for generics, and the growing aging population with various chronic diseases are responsible for market growth. However, the advent of COVID-19 led to a temporary shutdown of research and manufacturing activities of ancillary goods used for manufacturing drugs, which had impacted the supply chain and is likely to have a negative impact on the market growth.

Outsourcing allows pharmaceutical companies to focus on their core competencies such as sales and marketing rather than manufacturing and research. This is expected to have a positive impact on the market growth. However, the pharmaceutical companies practicing in-house manufacturing are increasing their investments with respect to production capabilities. This may limit the potential growth of contract manufacturing services to traditional customers, thereby hampering industrial growth.

The COVID-19 pandemic has provided new opportunities for pharmaceutical contract manufacturing and research services. Because of this pandemic, the contract service sector has switched its focus toward manufacturing and research of COVID-19 therapies and vaccines. For instance, in October 2020, CDMO Recipharm formed an agreement with Arcturus Therapeutics to support the manufacturing of its COVID-19 vaccine candidate—ARCT-021. Currently, it is in the phase 1/2 clinical trial. Similarly, in March 2022, the biotechnology company GeoVax partnered with a CRO CATO SMS to support GeoVAX in the Phase 2 trials of the COVID-19 Vaccine candidate GEO-CM04S1.

Service Insights

The manufacturing segment held the largest revenue share of over 66.0% in 2022. This segment is further segmented into API/bulk drugs manufacturing, advanced drug delivery formulations, packaging, and finished dose formulations. API dominated the market in 2021 as a consequence of the rising demand for High Potency Active Pharmaceutical Ingredients (HPAPI). Market entities are engaged in the development of large-scale manufacturing facilities on a pilot as well as commercial scale.

Finished dose formulations are anticipated to expand at the fastest CAGR of 7.8% over the forecast period. Among these, solid formulations accounted for the largest revenue share in 2022 due to the higher outsourcing done for the powdered formulations. It is expected to witness gradual expansion in the coming years as it represents a significant share of the outsourcing of finished dose formulations. Solid dose manufacturing and oral delivery of new drug candidates, fixed-dose combinations, controlled release dosage forms, and reformulation of existing drugs are some of the factors likely to accelerate the growth of contract manufacturing of solid dosage formulations.

Regional Insights

Asia Pacific dominated the market with a revenue share of over 41.9% in 2022 and is projected to grow at a significant rate over the forecast period. This growth is supported by a rise in the number of companies outsourcing projects in the developing economies of this region. In recent years, countries such as Singapore, China, and India have been observed as major players in the pharmaceutical industry owing to their expanding manufacturing capabilities. The cash-rich nature of the Asian companies is responsible for the captive nature of the contract manufacturing sector. The spout of significant investments by Asian CMOs is expected to result in exponential progress.

The Latin American market is anticipated to witness substantial growth over the forecast period as a consequence of the presence of established multinational players in this region. Major entities operating in Brazil are Novartis, Roche, and Pfizer. Latin America holds the potential for transforming into a global hub for the development and production of pharmaceutical products. Factors that are responsible for this transformation include the low cost of product development

Some of the prominent players in the Pharmaceutical Contract Manufacturing And Research Services Market include:

  • Catalent
  • Pharmaceutical Product Development LLC
  • AbbVie
  • Baxter BioPharma Solutions
  • Patheon
  • Grifols International, S.A.
  • Dalton Pharma Services
  • Boehringer Ingelheim Biopharmaceuticals GmbH
  • Lonza AG

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2032. For this study, Nova one advisor, Inc. has segmented the global Pharmaceutical Contract Manufacturing And Research Services market.

By Service 

  • Manufacturing
    • API/Bulk Drugs
    • Advanced Drug Delivery Formulations Packaging
    • Packaging
    • Finished Dose Formulations
      • Solid Formulations
      • Liquid Formulations
      • Semi-solid Formulations
  • Research
    • Oncology
    • Vaccines
    • Inflammation & Immunology
    • Cardiology
    • Neuroscience
    • Others

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East & Africa (MEA)

Chapter 1 Methodology and Scope
                   1.1 Market Segmentation & Scope
                       1.1.1 Service
                       1.1.2 Regional Scope
                       1.1.3 Estimates And Forecast Timeline
                   1.2 Research Methodology
                   1.3 Information Procurement
                       1.3.1 Purchased Database
                       1.3.2 Nova one advisor’s Internal Database
                       1.3.3 Secondary Sources
                       1.3.4 Primary Research
                       1.3.5 Details Of Primary Research
                   1.4 Information or Data Analysis
                       1.4.1 Data Analysis Models
                   1.5 Market Formulation & Validation
                   1.6 Model Details
                       1.6.1 Commodity Flow Analysis (Model 1)
                       1.6.2 Volume Price Analysis (Model 2)
                   1.7 List of Secondary Sources
                   1.8 List of Primary Sources
                   1.9 List of Abbreviations
                   1.10 Objectives
                       1.10.1 Objective - 1
                       1.10.2 Objective - 2
                       1.10.3 Objective - 3
                       1.10.4 Objective - 4
Chapter 2 Executive Summary
                   2.1 Market Outlook
Chapter 3 Pharmaceutical Contract Manufacturing & Research Market: Variables, Trends, & Scope
                   3.1 Market Segmentation and Scope
                   3.2 Market Driver Analysis
                       3.2.1 Drug shortage driving demand for pharmaceutical development
                       3.2.2 Commercial success of biologics for clinical use
                       3.2.3 Lower manufacturing costs and improving economic condition of BRIC
                   3.3 Market Restraint Analysis
                       3.3.1 Limited outsourcing opted by big pharma companies
                       3.3.2 Regulatory issues pertaining to the drug approval
                   3.4 Penetration & Growth Prospect Mapping
                   3.5 Porter’s Five Forces Analysis
                   3.6 PESTEL Analysis
                   3.7 COVID-19 Analysis
Chapter 4 Pharmaceutical Contract Manufacturing & Research Market: Services Segment Analysis
                   5.1 Pharmaceutical Contract Manufacturing & Research Market: Market Share Analysis, 2023 & 2032
                   5.2 Manufacturing
                       5.2.1 Manufacturing market, 2020 - 2032
                       5.2.2 API/Bulk Drugs
                           5.2.2.1 API/Bulk Drugs market, 2020 - 2032
                       5.2.3 Advanced Drug Delivery Formulations
                           5.2.3.1 Advanced Drug Delivery Formulations market, 2020 - 2032
                       5.2.4 Packaging
                           5.2.4.1 packaging market, 2020 - 2032
                       5.2.5 Finished Dose Formulations
                           5.2.5.1 Finished Dose Formulations market, 2020 - 2032
                           5.2.5.2 Solid
                               5.2.5.2.1 Solid market, 2020 - 2032
                           5.2.5.3 Liquid
                               5.2.5.3.1 Liquid market, 2020 - 2032
                           5.2.5.4 Semi-solid formulations
                               5.2.5.4.1 Semi-solid formulations market, 2020 - 2032
                   5.3 Research
                       5.3.1 Research market, 2020 - 2032
                       5.3.2 Oncology
                           5.3.2.1 Oncology market, 2020 - 2032
                       5.3.3 Vaccines
                           5.3.3.1 Vaccines market, 2020 - 2032
                       5.3.4 Inflammation & Immunology
                           5.3.4.1 Inflammation & Immunology market, 2020 - 2032
                       5.3.5 Cardiology
                           5.3.5.1 Cardiology market, 2020 - 2032
                       5.3.6 Neuroscience
                           5.3.6.1 Neuroscience market, 2020 - 2032
                       5.3.7 Others
                           5.3.7.1 Others market, 2020 - 2032
Chapter 6 Pharmaceutical Contract Manufacturing & Research Market: Regional Analysis
                   6.1 Pharmaceutical Contract Manufacturing & Research Market: Market Share Analysis, 2023 & 2032
                   6.2 North America
                       6.2.1 North America Pharmaceutical Contract Manufacturing & Research Market, 2020 - 2032
                       6.2.2 U.S.
                           6.2.2.1 U.S. Pharmaceutical Contract Manufacturing & Research Market, 2020 - 2032
                       6.2.3 Canada
                           6.2.3.1 Canada Pharmaceutical Contract Manufacturing & Research Market, 2020 - 2032
                   6.3 Europe
                       6.3.1 Europe Pharmaceutical Contract Manufacturing & Research Market, 2020 - 2032
                       6.3.2 Germany
                           6.3.2.1 Germany Pharmaceutical Contract Manufacturing & Research Market, 2020 - 2032
                       6.3.3 France
                           6.3.3.1 France Pharmaceutical Contract Manufacturing & Research Market, 2020 - 2032
                       6.3.4 Italy
                           6.3.4.1 Italy Pharmaceutical Contract Manufacturing & Research Market, 2020 - 2032
                       6.3.5 Spain
                           6.3.5.1 Spain Pharmaceutical Contract Manufacturing & Research Market, 2020 - 2032
                       6.3.6 U.K.
                           6.3.6.1 U.K. Pharmaceutical Contract Manufacturing & Research Market, 2020 - 2032
                   6.4 Asia Pacific
                       6.4.1 Asia Pacific Pharmaceutical Contract Manufacturing & Research Market, 2020 - 2032
                       6.4.2 China
                           6.4.2.1 China Pharmaceutical Contract Manufacturing & Research Market, 2020 - 2032
                       6.4.3 India
                           6.4.3.1 India Pharmaceutical Contract Manufacturing & Research Market, 2020 - 2032
                       6.4.4 Japan
                           6.4.4.1 Japan Pharmaceutical Contract Manufacturing & Research Market, 2020 - 2032
                       6.4.5 Australia
                           6.4.5.1 Australia Pharmaceutical Contract Manufacturing & Research Market, 2020 - 2032
                   6.5 Latin America
                       6.5.1 Latin America Pharmaceutical Contract Manufacturing & Research Market, 2020 - 2032
                       6.5.2 Brazil
                           6.5.2.1 Brazil Pharmaceutical Contract Manufacturing & Research Market, 2020 - 2032
                       6.5.3 Mexico
                           6.5.3.1 Mexico Pharmaceutical Contract Manufacturing & Research Market, 2020 - 2032
                       6.5.4 Argentina
                           6.5.4.1 Argentina Pharmaceutical Contract Manufacturing & Research Market, 2020 - 2032
                       6.5.5 Colombia
                           6.5.5.1 Colombia Pharmaceutical Contract Manufacturing & Research Market, 2020 - 2032
                       6.5.6 Chile
                           6.5.6.1 Chile Pharmaceutical Contract Manufacturing & Research Market, 2020 - 2032
                       6.5.7 VENEZUELA
                           6.5.7.1 venezuela Pharmaceutical Contract Manufacturing & Research Market, 2020 - 2032
                   6.6 MEA
                       6.6.1 MEA Pharmaceutical Contract Manufacturing & Research Market, 2020 - 2032
                       6.6.2 South Africa
                           6.6.2.1 South Africa Pharmaceutical Contract Manufacturing & Research Market, 2020 - 2032
                       6.6.3 Saudi Arabia
                           6.6.3.1 Saudi Arabia Pharmaceutical Contract Manufacturing & Research Market, 2020 - 2032
Chapter 7 Competitive Landscape
                   7.1 Strategy Framework
                   7.2 Market Participation Categorization
                   7.3 Company Profiles
                       7.3.1 Boehringer Ingelheim GmbH
                           7.3.1.1 Company overview
                           7.3.1.2 Financial performance
                           7.3.1.3 Product benchmarking
                           7.3.1.4 Strategic initiatives
                       7.3.2 Lonza
                           7.3.2.1 Company overview
                           7.3.2.2 Financial performance
                           7.3.2.3 Product benchmarking
                           7.3.2.4 Strategic initiatives
                       7.3.3 Grifols S.A
                           7.3.3.1 Company overview
                           7.3.3.2 Financial performance
                           7.3.3.3 Product benchmarking
                           7.3.3.4 Strategic initiatives
                       7.3.4 Jubilant Life Sciences Limited
                           7.3.4.1 Company overview
                           7.3.4.2 Financial performance
                           7.3.4.3 Product benchmarking
                           7.3.4.4 Strategic initiatives
                       7.3.5 Pfizer, Inc.
                           7.3.5.1 Company overview
                           7.3.5.2 Financial performance
                           7.3.5.3 Product benchmarking
                           7.3.5.4 Strategic initiatives
                       7.3.6 Charles River Laboratories International, Inc
                           7.3.6.1 Company overview
                           7.3.6.2 Financial performance
                           7.3.6.3 Product benchmarking
                           7.3.6.4 Strategic initiatives
                       7.3.7 Albany Molecular Research, Inc.
                           7.3.7.1 Company overview
                           7.3.7.2 Product benchmarking
                           7.3.7.3 Strategic initiatives
                       7.3.8 Covance, Inc. (LabCorp)
                           7.3.8.1 Company overview
                           7.3.8.2 Financial performance
                           7.3.8.3 Product benchmarking
                       7.3.9 IQVIA
                           7.3.9.1 Company overview
                           7.3.9.2 Financial performance
                           7.3.9.3 Product benchmarking
                           7.3.9.4 Strategic initiatives
                       7.3.10 Baxter BioPharma Solutions
                           7.3.10.1 Company overview
                           7.3.10.2 Financial performance
                           7.3.10.3 Product Benchmarking
                           7.3.10.4 Strategic initiatives
                       7.3.11 Aenova Holding GmbH
                           7.3.11.1 Company overview
                           7.3.11.2 Product Benchmarking
                       7.3.12 Vetter Pharma
                           7.3.12.1 Company Overview
                           7.3.12.2 Product benchmarking
                       7.3.13 Valeant Pharmaceuticals International Inc.
                           7.3.13.1 Company Overview
                           7.3.13.2 Financial performance
                           7.3.13.3 Product benchmarking
                       7.3.14 Ligand Pharmaceuticals, Inc.
                           7.3.14.1 Company Overview
                           7.3.14.2 Financial performance
                           7.3.14.3 Product benchmarking
                           7.3.14.4 Strategic initiatives
                       7.3.15 Pharmaceutical Product Development, LLC
                           7.3.15.1 Company Overview
                           7.3.15.2 Financial performance
                           7.3.15.3 Product benchmarking
                           7.3.15.4 Strategic initiatives
                       7.3.16 Recipharm AB.
                           7.3.16.1 Company Overview
                           7.3.16.2 Financial performance
                           7.3.16.3 Product benchmarking
                           7.3.16.4 Strategic initiatives
                       7.3.17 AbbVie, Inc.
                           7.3.17.1 Company Overview
                           7.3.17.2 Financial performance
                           7.3.17.3 Product benchmarking
                           7.3.17.4 Strategic initiatives
                       7.3.18 Famar Health Care Services
                           7.3.18.1 Company Overview
                           7.3.18.2 Product benchmarking
                           7.3.18.3 Strategic initiatives
                       7.3.19 Catalent Pharma Solutions
                           7.3.19.1 Company Overview
                           7.3.19.2 Financial performance
                           7.3.19.3 Product benchmarking
                           7.3.19.4 Strategic initiatives
                       7.3.20 West Pharmaceutical Services, Inc.
                           7.3.20.1 Company Overview
                           7.3.20.2 Financial performance
                           7.3.20.3 Product benchmarking
                           7.3.20.4 Strategic initiatives

Proceed To Buy

USD 4500
USD 3800
USD 1900
USD 1200

Customization Offered

  • check-img Cross-segment Market Size and Analysis for Mentioned Segments
  • check-imgAdditional Company Profiles (Upto 5 With No Cost)
  • check-img Additional Countries (Apart From Mentioned Countries)
  • check-img Country/Region-specific Report
  • check-img Go To Market Strategy
  • check-imgRegion Specific Market Dynamics
  • check-imgRegion Level Market Share
  • check-img Import Export Analysis
  • check-imgProduction Analysis
  • check-imgOthers